You just read:

Landmark TIOSPIR(TM) trial reinforces value of SPIRIVA(R) in two formulations as one of the leading maintenance therapies for chronic obstructive pulmonary disease (COPD)

News provided by

Boehringer Ingelheim (Canada) Ltd.

Sep 09, 2013, 06:59 ET